Pharmaceuticals

CONSUN PHARMA

Konchon Pharmaceutical Group to Hold Annual General Meeting in 2026

Kangchen Pharmaceutical Maintains Stable Base and High Dividends

CONSUN PHARMA released FY2025 Q3 earnings on March 26 (BJT), actual revenue HKD 1.011 B, actual EPS HKD 0.3717

CONSUN PHARMA released FY2025 9 Months Earnings on March 26 (BJT), actual revenue HKD 2.709 B, actual EPS HKD 0.9997

CONSUN PHARMA released FY2025 earnings on March 26 During-Market (BJT), actual revenue HKD 3.735 B (forecast HKD 3.811 B), actual EPS HKD 1.3771 (forecast HKD 1.4419)

CONSUN PHARMA released FY2025 Q4 earnings on March 26 During-Market (BJT), actual revenue HKD 1.028 B, actual EPS HKD 0.3781

CONSUN PHARMA to release FY2025 earnings on March 26, 2026, during market hours (BJT), with forecast revenue of HKD 3.749 B and EPS of HKD 1.4184

Konchon Pharmaceutical Repurchased 231,000 Shares

Konchon Pharmaceutical repurchased 200,000 shares for HKD 2,984,300

Kangchen Pharmaceutical Repurchased 70,000 Shares for HKD 1,052,000

Konchon Pharmaceutical repurchased 150,000 shares for HKD 2.237 million

Konchon Pharmaceutical Repurchased 292,000 Shares for HKD 4,067,800

Konchon Pharmaceuticals repurchased 170,000 shares for HKD2.52 million

Kangchen Pharmaceutical Repurchased 2,000 Shares for HKD 30,000

Konchon Pharmaceutical repurchased 505,000 shares

Konchon Pharmaceutical Repurchased 201,000 Shares for HKD 3,029,800

Konka Pharmaceutical repurchased 317,000 shares

Kangchen Pharmaceutical Shares Surge Benefiting from Chinese Medicine Policy Support

CONSUN PHARMA released FY2025 Q1 earnings on August 19 (BJT), actual revenue HKD 839.96 M, actual EPS HKD 0.3105

CONSUN PHARMA released FY2025 Q2 earnings on August 19 During-Market (BJT), actual revenue HKD 858.43 M, actual EPS HKD 0.3174

FAMEGLOW

HAICHANG HLDG

TJCD

NEW GONOW RV

CH DEMETER FIN

REF HOLDINGS

LUEN THAI

ZHONGSHENJIANYE

HUISHENG INTL

INTELLIMARK W27

Ordinary dividend (cash)

Ex Date: 2026.06.09, Cash dividend 0.4 HKD

01681

09926

06160

CONSUN PHARMA has recently shown a steady upward trend, with an increase of approximately 12.27%. The MACD daily bullish signal is gradually being established, with the fast and slow lines crossing above the zero axis, which usually indicates that the medium-term trend is transitioning from a consolidation phase to an upward breakout. The trading volume is about HKD 72.39 million, which, although not a large absolute amount, has significantly increased compared to the stock's historical average daily volume, indicating a rise in capital participation. The stock price is steadily rising, and the short-term moving averages are beginning to turn upward, forming an initial bullish arrangement. On the news front, the overall recovery trend in the pharmaceutical sector is evident. The Hong Kong stock biopharmaceutical index has stabilized and rebounded, with AKESO rising over 4% on the day and BEONE MEDICINES increasing nearly 3%, showing clear signs of capital returning to the sector. As a leader in the traditional Chinese medicine nephrology field, CONSUN PHARMA has a stable product matrix and excellent cash flow performance, making it a defensive yet flexible choice in the rotation of the pharmaceutical sector. Additionally, the domestic medical insurance policy's supportive stance towards traditional Chinese medicine remains unchanged, and the impact of centralized procurement on exclusive varieties is limited. The company's fundamentals are relatively certain, attracting some funds seeking stable returns. From a technical perspective, the current stock price is operating above the 5-day and 10-day moving averages, with both moving averages trending upward and maintaining a moderate distance, forming a step-like support. If today's trading volume remains above HKD 70 million and holds above the 5-day moving average, the upward trend is expected to continue. Attention should be paid to the previous high-pressure zone above, as a breakthrough may open up new upward space. The correlation between the Hong Kong pharmaceutical sector and the A-share market is worth noting, as the A-share market has also been active in the innovative drug sector recently

Technical Forecast

AKESO

BEONE MEDICINES

Pre-market trend | CONSUN PHARMA (1681.HK) 5/6 moderately increased with volume, is capital flowing back into the pharmaceutical sector?

Consun Pharmaceutical Group Ltd. reported a 15.2% revenue increase to RMB3.42 billion and an 18.4% rise in net profit to RMB1.08 billion for the year ending December 31, 2025. Basic earnings per share rose to RMB1.27. The company proposed a final dividend of HKD0.40 per share, reflecting confidence in cash generation. Analysts rate the stock as a Buy with a target price of HK$19.50. Consun operates in the pharmaceutical sector, primarily selling prescription drugs in mainland China and other markets.

Tip Ranks

Consun Pharmaceutical Posts Double-Digit Profit Growth and Raises Shareholder Payout

512290

513060

159316

513700

513120

510660

CONSUN PHARMA announced its full-year results for the year ended last December, with revenue of RMB 3.417 billion, an increase of 15.2% year-on-year. Net profit was RMB 1.078 billion, an increase of 18.4% year-on-year; earnings per share were RMB 1.27. A final dividend of HKD 0.4 was declared, compared to HKD 0.3 in the same period last year

AASTOCKS

Guotai CSI Bio-medicine ETF

Bosera Hang Seng Health Care ETF(QDII)

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

Hwabao WP CSI Pharmaceuticals ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

E Fund CSI 300 Health Care ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

China Universal 800 Health Care ETF

Guotai SSE STAR Brand Name Drug ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Yinhua CSI Innovative Drugs Industry ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

"Performance" CONSUN PHARMA's annual net profit is RMB 1.078 billion, an increase of 18.4%, with a final dividend of HKD 0.4

Consun Pharmaceutical Group Ltd. has expanded its share buyback program by an additional HKD100 million, raising the total to HKD300 million, representing up to 10% of its issued share capital. This decision reflects management's confidence in the company's fundamentals and aims to optimize capital structure while enhancing per-share metrics. The buybacks will be funded from existing cash resources, with execution depending on market conditions. The latest analyst rating for the stock is a Buy, with a price target of HKD20.50.

Consun Pharma Expands Share Buyback to HKD300 Million Amid Confidence in Growth Outlook

According to the Zhitong Finance APP, CONSUN PHARMA announced that on November 3, 2025, the company spent HKD 3.0298 million to repurchase 201,000 shares

Zhitong

On November 3rd, CONSUN PHARMA spent HKD 3.0298 million to repurchase 201,000 shares

According to the Zhitong Finance APP, CONSUN PHARMA announced that it spent HKD 5.259 million to repurchase 350,000 shares on October 31, 2025

On October 31st, CONSUN PHARMA spent HKD 5.259 million to repurchase 350,000 shares

According to the Zhitong Finance APP, CONSUN PHARMA announced that it spent HKD 4.205 million to repurchase 280,000 shares on October 30, 2025

On October 30th, CONSUN PHARMA spent HKD 4.205 million to repurchase 280,000 shares

According to the Zhitong Finance APP, CONSUN PHARMA announced that the company repurchased 159,000 shares at a cost of HKD 2.4497 million on October 28, 2025, with a repurchase price per share ranging from HKD 15.26 to HKD 15.43

On October 28th, CONSUN PHARMA spent HKD 2.4497 million to repurchase 159,000 shares

According to the Zhitong Finance APP, CONSUN PHARMA announced that on October 27, 2025, the company spent HKD 1.54 million to repurchase 100,000 shares

On October 27th, CONSUN PHARMA spent HKD 1.54 million to repurchase 100,000 shares

CONSUN PHARMA(01681.HK)